Sales and Marketing

Showing 15 posts of 11524 posts found.

NICE recommends Bayer’s Xofigo for prostate cancer treatment

September 2, 2016 Medical Communications, Sales and Marketing Bayer, NICE, approval, prostate cancer, recommendation, xofigo

NICE has issued final draft guidance recommending Bayer’s Xofigo (radium-223 dichloride) for the treatment of prostate cancer. Previously, the drug …

Sepha is fast packing with a new EZ Blister upgrade.

September 1, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Packaging Equipment Specialist, Sepha, has released a functional upgrade for one of its original products, EZ Blister, the lab scale …
cloud

Cloud on the horizon: Cloud computing and the clinical trial

September 1, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cloud Computing, ICON, clinical trials, ibm

 Originally published in the September edition of Pharmafocus, Matt Fellows investigates how cloud computing may just be the answer the …

Eli Lilly elects Jamere Jackson to board of directors

September 1, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, appointment

Eli Lilly has elected Jamere Jackson to its board of directors, effective 1 October, where he will serve on the …
pfizer_chrome_plate

Pfizer nabs EU approval for Xalkori for certain lung cancers

August 31, 2016 Sales and Marketing Pfizer, Xalkori, lung cancer, non-small cell lung cancer

The European Commission has approved Pfizer’s Xalkori (crizotinib) for the treatment of adults with ROS1-positive advanced non-small cell lung cancer …

Recipharm establishes long term supply agreement with Tillotts Pharma AG

August 31, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Recipharm, the contract development and manufacturing organisation (CDMO), announces that it has entered into a long term supply agreement with …
novartis_building

FDA approves Novartis Enbrel biosimilar

August 31, 2016 Research and Development, Sales and Marketing Enbrel, FDA, Novartis, Sandoz, biosimilar, erzeli

Novartis, through its Sandoz division, has announced that the FDA has approved Erelzi (etanercept-szzs), a biosimilar of Amgen’s blockbuster drug …
shkreli_kalobios

KaloBios cuts ties with former CEO Martin Shkreli, outlines ‘maniacal’ turnaround plan

August 30, 2016 Research and Development, Sales and Marketing Daraprim, KaloBios, Martin Shkreli, Retrophin, benznidazole, turnaround

Two months after small drugmaker KaloBios returns from bankruptcy, controversial industry figure Martin Shkreli is no longer a stakeholder in …

Cipla receives FDA approval for generic version of Valeant antidepressant

August 30, 2016 Manufacturing and Production, Sales and Marketing Cipla, FDA, Valeant, Wellbutrin

Indian multinational pharma and biotech company Cipla has announced that its US arm InvaGen Pharmaceuticals has received approval from the …
top_ten

Top ten stories in the pharmaceutical industry this week

August 26, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharmafile, top 10

If this week left you feeling with a sense of déjà vu, you could certainly be forgiven. With US politicians …
chemo-web

Boost for Clovis as FDA grants priority review for rucaparib in ovarian cancer

August 25, 2016 Research and Development, Sales and Marketing FDA, clovis, ovarian cancer, rucaparib

Clovis Oncology has announced that the US Food and Drug Administration has accepted its new drug application for rucaparib, and …
teva_copy

Teva loses patent protection on lucrative MS treatment

August 25, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, Mylan, Teva, multiple sclerosis

Teva’s stock plunged 3% after a US agency ruled that two of its patents related to multiple sclerosis drug Copaxone …
amgen_flag

FDA says no to Amgen’s Parsabiv

August 25, 2016 Research and Development, Sales and Marketing Amgen, FDA, par

Amgen has announced that the US Food and Drug Administration (FDA) has issued a complete response letter rejecting Parsabiv (etelcalcetide) …
fdaoutsideweb

Medical device user fees to increase 68% for 2018 to 2022

August 25, 2016 Research and Development, Sales and Marketing FDA, Medical device

The Food and Drug Administration has reached an agreement with the medical device industry and laboratory community on proposed recommendations …
The Gateway to Local Adoption Series

Latest content